Fig. 3.

a Overall and disease specific (G43*) visits and sick leave days per patient-year in controls (white) and the primary cohort [no prescriptions (grey), acute prescriptions (dark grey), prophylactic prescriptions (black)]. Significance in indicated between controls and migraine patients, as well as between migraine groups. b Overall and migraine specific visits and sick leave days per patient-year by prophylactic treatment line. No prophylactic prescriptions (white); 1st prophylactic treatment line (light grey); 2nd prophylactic treatment line (dark grey); 3rd or more treatment line (black). Significance is indicated between four groups. *p < 0.001